Merck & Co. Inc. stock (US58933Y1055): shares jump after strong move toward upper 52-week range

Merck & Co. Inc. shares moved sharply higher toward the top end of their 52-week range after a 4.8% gain on 06/04/2026, keeping the U.S. pharma heavyweight in focus on the New York Stock Exchange.

Merck & Co. Inc. shares have drawn renewed attention on the New York Stock Exchange after the stock advanced 4.8% to close at USD 120.26 on 06/04/2026, bringing it close to the upper end of its 52-week trading band, according to data cited by GuruFocus as of 06/04/2026.GuruFocus as of 06/04/2026

This move keeps the United States-based blue chip, listed on the NYSE under the ticker MRK, in focus for investors tracking large pharmaceutical names with shares trading in U.S. dollars.

As of: 05.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Merck & Co.
• Sector/industry: Pharmaceuticals and life sciences
• Headquarters/country: Rahway, United States
• Core markets: United States, Europe, Asia-Pacific, Latin America
• Key revenue drivers: Human prescription medicines, vaccines, oncology therapies, animal health products
• Home exchange/listing venue: New York Stock Exchange (MRK)
• Trading currency: USD

Merck & Co. Inc.: core business model

Merck & Co. Inc. focuses on researching, developing and commercializing innovative human medicines, vaccines and animal health therapies, with a portfolio built around treatments for cancer, infectious diseases and chronic conditions that drive the bulk of its revenue.

Valuation metrics and multiples for Merck & Co. Inc.

The recent price action in Merck & Co. Inc. stock has also highlighted questions around valuation, particularly as the share price has approached levels near the upper end of its documented 52-week range of USD 76.66 to USD 125.14, based on figures reported by GuruFocus as of 06/04/2026.GuruFocus as of 06/04/2026

GuruFocus estimated a GF Value, its proprietary intrinsic value indicator, of USD 118.24 for Merck & Co. Inc. as of 06/04/2026, implying the closing price of USD 120.26 on that date was about 1.7% above this valuation yardstick, which suggests the shares were trading modestly richer than that particular model's fair value assessment.GuruFocus as of 06/04/2026

Conclusion

Merck & Co. Inc. remains in the spotlight on the New York Stock Exchange after its 4.8% share price gain to USD 120.26 on 06/04/2026 brought the stock closer to the top of its 52-week range.

Against this backdrop, valuation indicators such as the GF Value estimate of USD 118.24 as of 06/04/2026 provide one reference point for how the current market price compares with a modeled intrinsic value for the U.S. pharmaceutical group.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.